Clinical Trial

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

Study acronym: GenTLE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2023-09-25; most recent amendment 2026-05-28.
Status change: Not Yet Recruiting → Recruiting 2023-11-13
Trial Details
NCT Number NCT06063850
Lead Sponsor UniQure Biopharma B.V.
Conditions Mesial Temporal Lobe Epilepsy
Enrollment 12 participants
Start Date 2024-06-12
Primary Completion 2026-11-30 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-29